Avrobio (NASDAQ:AVRO) announced its earnings results on Thursday. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.09, Bloomberg Earnings reports.
Shares of AVRO traded down $0.80 during midday trading on Friday, hitting $19.24. The company had a trading volume of 282,135 shares, compared to its average volume of 747,012. The company has a 50-day moving average price of $18.24. The firm has a market capitalization of $483.91 million, a price-to-earnings ratio of -5.31 and a beta of 2.70. Avrobio has a 1 year low of $11.85 and a 1 year high of $53.70.
In related news, Director Bruce Booth acquired 810,811 shares of the firm’s stock in a transaction dated Friday, July 19th. The stock was acquired at an average price of $18.50 per share, for a total transaction of $15,000,003.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 4.70% of the company’s stock.
Avrobio Company Profile
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Recommended Story: Why is the conference call important?
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.